货号:A137399
同义名:
Compound C; BML-275
Dorsomorphin 是一种选择性、ATP 竞争性的 AMPK 抑制剂 (在没有 AMP 的情况下,Ki 为 109 nM),选择性抑制 BMP I 型受体 ALK2、ALK3 和 ALK6,并可逆转 Urolithin A导致的自噬激活和抗炎作用。Dorsomorphin可促进人类多能干细胞分化为神经祖细胞,促进小鼠和人类多能干细胞分化为心肌细胞,促进人类间充质细胞的脂肪分化,抑制成骨细胞的分化。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | Dorsomorphin, known as compound C, is a reversible selective ATP-competitive inhibitor of AMPK with Ki of 109 nM. Dorsomorphin can also inhibit the bone morphogenic protein (BMP) signaling and do not effect the expression of several structurally related kinases including ZAPK, SYK, PKCq, PKA, and JAK3[3]. In addition, dorsomorphin could stimulate the oxidation of long chain fatty acids independently in adipocytes by increasing carnitine palmitoyltransferase-1 (CPT1) activity[4] and remarkly reduce the adipogenic Differentiation of 3T3-L1 cells at 10 μM[5]. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway[6]. In vivo, dorsomorphin induces dorsalization in zebrafish embryos and the differentiation of osteoblast[7]. |
| Concentration | Treated Time | Description | References | |
| U937 cells | 5 μM | 24 h | Enhanced cell death induced by navitoclax, S63845, or A-1155463. | Cell Death Differ. 2024 Apr;31(4):405-416. |
| Hep3B cells | 10 µM | 16 h | Dorsomorphin inhibited BMP2- and HJV-induced hepcidin promoter activity. | Nat Chem Biol. 2008 Jan;4(1):33-41. |
| MRC-5 fetal lung fibroblasts | 1 μM | 4 days | Dorsomorphin synergizes with FSK to promote neuronal survival and maturation, although independently DM has no effect on neuronal conversion. | Nat Commun. 2013;4:2183. |
| IMR-90 fetal lung fibroblasts | 1 μM | 4 days | Dorsomorphin synergizes with FSK to promote neuronal survival and maturation, although independently DM has no effect on neuronal conversion. | Nat Commun. 2013;4:2183. |
| Clinical acute leukemia isolates | 5 μM | 24 h | Synergized with navitoclax, venetoclax, A-1155463, or S63845 to enhance cell death. | Cell Death Differ. 2024 Apr;31(4):405-416. |
| Jurkat cells | 5 μM | 24 h | Inhibited navitoclax- or S63845-induced AMPKα autophosphorylation and substrate phosphorylation, enhancing cell death. | Cell Death Differ. 2024 Apr;31(4):405-416. |
| C2C12 cells | 4 µM | 5 days | Dorsomorphin inhibited BMP4- and BMP6-induced alkaline phosphatase activity, indicating inhibition of BMP-induced osteogenic differentiation. | Nat Chem Biol. 2008 Jan;4(1):33-41. |
| Mouse pulmonary artery smooth muscle cells (PASMCs) | 0.47 µM | 30 min | Dorsomorphin inhibited BMP4-induced phosphorylation of BMP-responsive SMADs, without affecting MAPK p38 activation. | Nat Chem Biol. 2008 Jan;4(1):33-41. |
| Zebrafish embryos | 0.312 μM or 0.625 μM | To investigate the effects of DMP on zebrafish embryonic development, particularly on dorsoventral patterning. Results showed that DMP treatment caused dorsalization of embryos, similar to the phenotype induced by TDCIPP. | Environ Sci Technol. 2018 Sep 18;52(18):10820-10828. | |
| Saos2 cells | 5 μM | 24 h | To investigate the effect of Dorsomorphin on the migration and invasion of Saos2 cells, results showed that Dorsomorphin significantly inhibited the migration and invasion induced by TMEM119 overexpression. | Exp Mol Med. 2017 May 12;49(5):e329. |
| FOP fibroblasts | 1 μM | 25 days | Inhibited BMP-SMAD signaling, significantly reducing iPSC generation from FOP fibroblasts | Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13057-13062. |
| WT-hepatocytes | 10 µM | 9 h | Dorsomorphin completely restored the A23187-mediated inhibition of glycogen deposition, suggesting that the inhibitory effects of A23187 are mediated by AMPK signaling. | Mol Metab. 2024 Jun;84:101942. |
| WT-hepatocytes | 1, 3, or 10 µM | 9 h | Dorsomorphin reversed the ethanol-mediated inhibition of glycogen levels, indicating that ethanol suppresses glycogen deposition through the AMPK signaling pathway. | Mol Metab. 2024 Jun;84:101942. |
| 3T3-L1 fibroblasts | 1 μmol/mL | 24 h | To verify whether AMPK mediates the anti-fibrotic effect of ORM, results showed that dorsomorphin reversed the inhibitory effect of ORM on fibrotic markers | Acta Pharmacol Sin. 2022 Feb;43(2):367-375. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c Nude mice | Jurkat, U937, or MV-4-11 xenograft models | Intraperitoneal injection | 25 mg/kg | Three times a week for two weeks | The combination of dorsomorphin with navitoclax or S63845 significantly inhibited xenograft growth with minimal toxicity to normal tissues. | Cell Death Differ. 2024 Apr;31(4):405-416. |
| Zebrafish | Adult zebrafish | Intraperitoneal injection | 23 µg/g | Single injection | Dorsomorphin inhibited iron-induced hepatic SMAD1/5/8 phosphorylation and hepcidin expression. | Nat Chem Biol. 2008 Jan;4(1):33-41. |
| Zebrafish | Zebrafish embryos | Exposure in embryo media | 0.312 μM or 0.625 μM | Exposure initiated at 0.75 hpf | To investigate the effects of DMP on zebrafish embryonic development, particularly on dorsoventral patterning. Results showed that DMP treatment caused dorsalization of embryos, similar to the phenotype induced by TDCIPP. | Environ Sci Technol. 2018 Sep 18;52(18):10820-10828. |
| Rats | Streptozotocin-induced diabetic peripheral neuropathy model | Intraperitoneal injection | 0.2 mg/kg | Once daily for 15 days | To investigate the effect of Dorsomorphin on the protective role of Empagliflozin in diabetic peripheral neuropathy, results showed that Dorsomorphin almost completely abolished the beneficial effects of Empagliflozin. | Arch Pharm Res. 2022 Jul;45(7):475-493 |
| Dose | Mice: 3 mg/kg - 12 mg/kg[3] (i.p.) Rat: 0.2 mg/kg[4] (i.v.) |
| Administration | i.p., i.v. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.52mL 2.50mL 1.25mL |
25.03mL 5.01mL 2.50mL |
|
| CAS号 | 866405-64-3 |
| 分子式 | C24H25N5O |
| 分子量 | 399.49 |
| SMILES Code | C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1 |
| MDL No. | MFCD08705402 |
| 别名 | Compound C; BML-275 |
| 运输 | 蓝冰 |
| InChI Key | XHBVYDAKJHETMP-UHFFFAOYSA-N |
| Pubchem ID | 11524144 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Inert atmosphere,2-8°C |
| 溶解方案 |
DMSO: 35 mg/mL(87.61 mM),配合低频超声,并调节pH至2,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 1M HCl: 50 mg/mL(125.16 mM),配合低频超声,并调节pH至1 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1